Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children
This postmarketing surveillance study will evaluate the safety profile of Enbrel (etanercept) in an Indian population. It will provide surveillance on a currently approved indication for Enbrel of reducing symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.
|Study Design:||Time Perspective: Prospective|
|Official Title:||A Post-Marketing Surveillance Looking at Safety of Enbrel (Etanercept) in Adults With Active Rheumatoid Arthritis (RA) and Children With Juvenile Rheumatoid Arthritis (JRA).|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00484809
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|